ATE529107T1 - Ligustilid-derivate zur behandlung von entzündungserkrankungen - Google Patents

Ligustilid-derivate zur behandlung von entzündungserkrankungen

Info

Publication number: ATE529107T1
Authority: AT; Austria
Prior art keywords: formula; compounds; treatment; hydroxyl; manufacture
Prior art date: 2005-05-24

Application number

AT06753874T

Other languages

English (en)

Inventor

Ann Fowler

Daniel Raederstorff

Goede Schueler

Joseph Schwager

Original Assignee

Dsm Ip Assets Bv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-05-24

Filing date

2006-05-24

Publication date

2011-11-15

2006-05-24 Application filed by Dsm Ip Assets Bv filed Critical Dsm Ip Assets Bv

2011-11-15 Application granted granted Critical

2011-11-15 Publication of ATE529107T1 publication Critical patent/ATE529107T1/de

Links

IQVQXVFMNOFTMU-FLIBITNWSA-N (Z)-ligustilide Chemical class C1CC=CC2=C1C(=C/CCC)/OC2=O IQVQXVFMNOFTMU-FLIBITNWSA-N 0.000 title 1
208000027866 inflammatory disease Diseases 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 4
125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
238000004519 manufacturing process Methods 0.000 abstract 3
239000000203 mixture Substances 0.000 abstract 3
206010061218 Inflammation Diseases 0.000 abstract 2
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 abstract 2
125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 abstract 2
230000006378 damage Effects 0.000 abstract 2
230000004054 inflammatory process Effects 0.000 abstract 2
230000002265 prevention Effects 0.000 abstract 2
-1 1-butylidene Chemical group 0.000 abstract 1
241000124008 Mammalia Species 0.000 abstract 1
206010037660 Pyrexia Diseases 0.000 abstract 1
239000004480 active ingredient Substances 0.000 abstract 1
210000001188 articular cartilage Anatomy 0.000 abstract 1
239000003795 chemical substances by application Substances 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
229910052739 hydrogen Inorganic materials 0.000 abstract 1
239000001257 hydrogen Substances 0.000 abstract 1
125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
238000012423 maintenance Methods 0.000 abstract 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
230000008929 regeneration Effects 0.000 abstract 1
238000011069 regeneration method Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
- C07D307/88—Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Physical Education & Sports Medicine (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Rheumatology (AREA)
Pulmonology (AREA)
Orthopedic Medicine & Surgery (AREA)
Immunology (AREA)
Epidemiology (AREA)
Pain & Pain Management (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Dermatology (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Psychology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Coloring Foods And Improving Nutritive Qualities (AREA)
Medicines Containing Plant Substances (AREA)
Furan Compounds (AREA)

AT06753874T 2005-05-24 2006-05-24 Ligustilid-derivate zur behandlung von entzündungserkrankungen ATE529107T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP05011203		2005-05-24
PCT/EP2006/005005 WO2006125651A2 (en)	2005-05-24	2006-05-24	Ligustilide derivatives for the treatment of inflammatory disorders

Publications (1)

Publication Number	Publication Date
ATE529107T1 true ATE529107T1 (de)	2011-11-15

Family

ID=37054238

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT06753874T ATE529107T1 (de)	2005-05-24	2006-05-24	Ligustilid-derivate zur behandlung von entzündungserkrankungen

Country Status (8)

Country	Link
US (2)	US20090176873A1 (de)
EP (1)	EP1937250B1 (de)
JP (1)	JP2008542226A (de)
KR (1)	KR20080015802A (de)
CN (1)	CN101184484B (de)
AT (1)	ATE529107T1 (de)
ES (1)	ES2375302T3 (de)
WO (1)	WO2006125651A2 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP5339373B2 (ja) *	2006-07-14	2013-11-13	ディーエスエムアイピーアセッツビー．ブイ．	組成物および炎症障害の治療、共治療または予防のためのその使用
EP2049134A2 (de) *	2006-07-14	2009-04-22	DSMIP Assets B.V.	Zusammensetzungen mit hagebutte und anderen wirkstoffen zur behandlung von entzündlichen erkrankungen
WO2008006582A1 (en) *	2006-07-14	2008-01-17	Dsm Ip Assets B.V.	Compositions comprising magnolol or honokiol and other active agents for the treatment of inflammatory diseases
CN101991568B (zh) *	2009-08-12	2012-02-08	上海张江中药现代制剂技术工程研究中心	洋川芎内酯i在制备抗抑郁症药物、偏头痛药物及其他5-羟色胺能系统相关疾病药物中的应用
EP2504007B1 (de) *	2009-11-23	2018-04-11	BAGI Research Limited	Neue therapeutische verfahren zur behandlung von entzündungs- und autoimmunerkrankungen
CN102125548A (zh) *	2010-01-13	2011-07-20	石药集团恩必普药业有限公司	丁苯酞及其衍生物在制备治疗帕金森病的药物中的应用
US8927601B2 (en) *	2011-12-20	2015-01-06	National Dong Hwa University	Uses of N-butylidenephthalide in treating a liver injury and improving liver function
TWI460168B (zh) *	2012-08-10	2014-11-11	Univ China Medical	用於抑制運動神經元自體吞噬之醫藥組合物及其應用
RU2585372C1 (ru) *	2012-08-17	2016-05-27	Китайский Медицинский Университет	Фармацевтическая композиция для ингибирования аутофагии двигательных нейронов и её применение
CN102793696B (zh) *	2012-08-31	2014-09-10	甘肃中医学院	丁苯酞在制备治疗支气管哮喘药物中的应用
TWI487521B (zh) *	2013-03-12	2015-06-11	Hawking Biolog Technology Co Ltd	苯酞化合物之應用
US20140271568A1 (en) *	2013-03-12	2014-09-18	Hawking Biological Technology Co., Ltd	Method and kit for providing an increased expression of telomerase, brain-derived neurotrophic factor, stromal cell-derived factor-1, cxc chemokine receptor 4, and/or immune regulatory factor of stem cell
TWI511727B (zh)	2014-07-02	2015-12-11	Everfront Biotech Inc	苯酞化合物之應用
CN112451519A (zh) *	2014-07-28	2021-03-09	长弘生物科技股份有限公司	丁烯基苯酞的用途及将其制备为医药组合物的方法
JP6371898B2 (ja) *	2014-07-28	2018-08-08	易珈生技股▲ふん▼有限公司	ブチリデンフタリドの用途、その使用方法及びそれを使用して医薬組成物を製造する方法
TWI707040B (zh) *	2014-09-11	2020-10-11	台灣粒線體應用技術股份有限公司	一種用於治療退化性神經疾病的細胞、含有該細胞的醫藥組合物及其應用
TWI650125B (zh) *	2016-05-19	2019-02-11	長弘生物科技股份有限公司	用於延緩肺纖維化之發病及／或治療肺纖維化之藥劑
CN109069478B (zh) *	2016-05-23	2021-07-06	长弘生物科技股份有限公司	Z-亚丁基苯酞于活化自体免疫系统的应用
CN106432161A (zh) *	2016-07-19	2017-02-22	四川大学	一类3‑烃基‑5,6‑二氧取代苯酞化合物及其制备方法和用途
CN107669689B (zh) *	2017-11-07	2021-04-30	浙江大学	一种治疗慢性阻塞性肺病的气雾剂
CN109350620B (zh) *	2018-12-15	2019-08-06	谭志军	一种治疗卵巢癌的药物及其用途
CN109498617A (zh) *	2018-12-26	2019-03-22	南京中医药大学	藁本内酯在制备防治骨质疏松症药品中的应用
CN111617071B (zh) *	2019-02-27	2023-05-23	苏州凯祥生物科技有限公司	一种高尿酸血症药物组合物及用于治疗高尿酸血症的药物
CN109966288A (zh) *	2019-05-05	2019-07-05	嘉兴市第二医院	一种治疗或预防动脉粥样硬化药物及应用
CN110169965B (zh) *	2019-05-28	2021-10-08	江苏康缘药业股份有限公司	一种化合物在治疗软骨退变性疾病方面的应用
CN114209691A (zh) *	2022-01-06	2022-03-22	正大青春宝药业有限公司	一种洋川芎内酯i复合物及在治疗心肌肥大疾病中的应用
JP2024027641A (ja) *	2022-08-18	2024-03-01	日本メナード化粧品株式会社	皮膚外用剤及び内用剤
CN118324730A (zh) *	2023-01-12	2024-07-12	陕西中医药大学	苯酞类化合物及其应用
CN116115603A (zh) *	2023-02-06	2023-05-16	北京中医药大学东直门医院	产紫青霉内酯c在制备抗炎或促进组织损伤愈合药物中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH01199958A (ja) *	1987-07-23	1989-08-11	Tsumura & Co	新規なフタリド誘導体およびその製造方法
JPS6450818A (en) *	1987-08-20	1989-02-27	Tsumura & Co	Prostaglandin f2alpha-inhibitor
JPH01207233A (ja) *	1988-02-12	1989-08-21	Tsumura & Co	抗動脈硬化症剤
JPH0477480A (ja) *	1990-07-19	1992-03-11	Tsumura & Co	フタリド誘導体
EP0500233A2 (de)	1991-02-14	1992-08-26	National Semiconductor Corporation	Bipolartransistorstruktur und BICMOS IC-Herstellungsverfahren
WO1995000157A1 (en) *	1993-06-25	1995-01-05	Mobius Consultancy Pty. Ltd.	Therapeutic agent
WO2002008188A1 (en) *	2000-07-25	2002-01-31	Merck & Co., Inc.	N-substituted indoles useful in the treatment of diabetes
US6407250B1 (en) *	2000-09-14	2002-06-18	Allergan Sales, Inc.	Interphenylene 7-oxabicyclic [2.2.1] heptane oxazoles as prostaglandin F2a antagonists
EP1622605B1 (de) *	2003-05-14	2009-07-15	DSM IP Assets B.V.	Verwendung von pthalide derivativen zur behandlung und prevention von diabetes mellitus
CN1569848A (zh) *	2003-07-14	2005-01-26	中国中医研究院中药研究所	治疗缺血性心脏病的川芎内酯及其制备方法
CN1302775C (zh) *	2003-11-25	2007-03-07	中国人民解放军第二军医大学	藁本内酯用于防治动脉粥样硬化的用途

2006
- 2006-05-24 WO PCT/EP2006/005005 patent/WO2006125651A2/en not_active Ceased
- 2006-05-24 ES ES06753874T patent/ES2375302T3/es active Active
- 2006-05-24 CN CN2006800182412A patent/CN101184484B/zh not_active Expired - Fee Related
- 2006-05-24 KR KR1020077027212A patent/KR20080015802A/ko not_active Ceased
- 2006-05-24 AT AT06753874T patent/ATE529107T1/de not_active IP Right Cessation
- 2006-05-24 US US11/920,346 patent/US20090176873A1/en not_active Abandoned
- 2006-05-24 EP EP06753874A patent/EP1937250B1/de not_active Not-in-force
- 2006-05-24 JP JP2008512773A patent/JP2008542226A/ja not_active Withdrawn
2010
- 2010-06-18 US US12/801,646 patent/US20100298427A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EP1937250B1 (de)	2011-10-19
CN101184484A (zh)	2008-05-21
EP1937250A2 (de)	2008-07-02
CN101184484B (zh)	2011-10-05
WO2006125651A3 (en)	2007-07-19
WO2006125651A2 (en)	2006-11-30
KR20080015802A (ko)	2008-02-20
US20100298427A1 (en)	2010-11-25
US20090176873A1 (en)	2009-07-09
ES2375302T3 (es)	2012-02-28
JP2008542226A (ja)	2008-11-27

Legal Events

Date	Code	Title	Description
2012-04-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE529107T1 (de)	2011-11-15	Ligustilid-derivate zur behandlung von entzündungserkrankungen
MX2007013065A (es)	2008-01-14	Derivados de dihidrobenzofurano y usos de los mismos.
IS8502A (is)	2006-06-08	Azatvíhringja heteróhringir sem kannabínóíð-viðtakastillar
EA200602062A1 (ru)	2007-04-27	Амидосоединения и их применение в качестве фармацевтических средств
SE0403006D0 (sv)	2004-12-09	New compounds
ATE435210T1 (de)	2009-07-15	Tetrahydroisochinolylacetamidderivate zur verwendung als orexinrezeptorantagonisten
ES2311803T3 (es)	2009-02-16	Composiciones embolicas de silicie pirogena.
ATE360631T1 (de)	2007-05-15	Azabicyclische heterocyclen als modulatoren des cannabinoidrezeptors
WO2004013120A8 (en)	2005-04-14	Novel benzodioxoles
ATE413388T1 (de)	2008-11-15	Muskarin antagonisten
ATE372124T1 (de)	2007-09-15	Zusammensetzung und verfahren zur perkutanen superoxygenierung
DE602004008098D1 (de)	2007-09-20	Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren
WO2006044362A3 (en)	2006-12-07	N-sulfonylpiperidine cannabinoid receptor 1 antagonists
DE602004012858D1 (de)	2008-05-15	2-aminobenzothiazole als cb1 rezeptor inverse agonisten
DE602005008558D1 (de)	2008-09-11	Kondensierte heterocyclische verbindungen und deren verwendung als antagonisten des metabotropen reznkungen
ATE491446T1 (de)	2011-01-15	Ligustilid zur behandlung von erkrankungen des zentralen nervensystems
ATE384058T1 (de)	2008-02-15	Thiazolderivate
DK1765816T3 (da)	2010-06-14	Substituerede 1-propinylpiperaziner med affinitet for MGluR5-receptoren til behandling af smertetilstande
UA83917C2 (en)	2008-08-26	3-(4-heteroarylcyclohexylamino) cyclopentanecarboxamides as modulators of chemokine receptors
BR0308184A (pt)	2005-01-11	Composição oftálmica compreendendo ascomicina
DE602004011204D1 (de)	2008-02-21	Quinoxalin-3-on-verdindungen als orexin-rezeptor antagonisten.
NO20064238L (no)	2006-11-20	Imidazolinderivater med CB1 agonistlsk aktivitet
ATE432278T1 (de)	2009-06-15	Verbindungen zur behandlung von krankheiten
DE602006010738D1 (de)	2010-01-07	Pyrroloä2,3-cüpyridinderivate
BR0105787A (pt)	2002-05-28	Composição farmacêutica, uso de um composto farmacêutico, método para tratamento de distúrbios, composto farmacêutico e método para confeccionar um composto farmacêutico